NICE approves AstraZeneca-targeted cancer drug Lynparza for treatment of patients with advanced ovarian cancer

recently, the National Institutes of Health and Clinical Optimization (NICE) approved AstraZeneca's anti-cancer drug Lynparza (Chinese brand name: Lipdro, generic name: olaparib, Olapari tablets) for patients with advanced ovarian cancer with brca mutations (BRCAm) that are remission after first-line platinum-containing chemotherapySuch patients are: patients with advanced (FIGO phase: phase III and IV) epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with BRCA1/2 mutationNICE's decision is based on the results of the critical Phase III clinical study SOLO-1The results showed that Lynparza achieved a statistically significant and clinically significant improvement in progressionless (PFS) compared to placebo, reduced the risk of disease progression or death by 70% (HR?0.30.30.25%CI-0.23-0.41), p.001)After 41 months of follow-up, the pfS in the Lynparza treatment group did not reach, and the placebo group was 13.8 monthsIn the Lynparza treatment group, 60.4 percent of patients did not progress after three years of treatment, compared with 26.9 percent in the placebo groupIn this study, Lynparza's safety characteristics were consistent with previous studiesAbout Lynparza
Lynparza is a pioneering, oral PARP inhibitor that prioritizes the use of defects in DNA repair pathways to kill cancer cells, a mode of action that gives Lynparza the potential to treat a wide range of types of tumors with DNA repair defectsPARP is associated with a wide range of tumor types, especially breast and ovarian cancerLynparza, the world's first PARP inhibitor, was first approved in December 2014 by the U.SFDA(http://for advanced ovarian cancer patients carrying harmful or suspected harmful type BRCA mutations (gBRCAm)To date, Lynparza has been approved by more than 60 countries around the world to maintain treatment for platinum-sensitive recurrent ovarian cancer, regardless of BRCA statusIn addition, Lynparza has been approved by the United States, Canada, Japan, Australia for the previous chemotherapy of the type of BRCA mutation HER2 negative metastatic breast cancer, in the European Union this indication includes localized advanced breast cancer patients 　　In the Chinese market, Lynparza was approved by China's National Drug (http:// Regulatory Authority (CNDA) on August 23, 2018 for the maintenance of platinum-sensitive recurrent ovarian cancer